ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction

Inclusion Criteria: 1. Age ≥18 and \<75 years; 2. First-time acute anterior STEMI; 3. The time from onset of ischemic symptom to the time of initial PCI balloon inflation ≤6 hours; 4. \>0.1 mV ST segment elevation in at least two contiguous precordial leads according to electrocardiogram; 5. Scheduled for primary PCI; 6. The presence of left anterior descending branch (LAD) occlusion in proximal or middle segment with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram; 7. Written informed consent. Exclusion Criteria: 1. Hypertrophic cardiomyopathy, aortic valve stenosis and/or regurgitation, pericarditis, or myocarditis; 2. Cardiogenic shock, severe ventricular arrhythmia, serious heart failure (Killip class III and above) or mechanical complications; 3. Patients after cardiopulmonary resuscitation (CPR) (including cardioversion); 4. Patients who have already received thrombolytic therapy; 5. Prior myocardial infarction or coronary artery bypass surgery; 6. Known serious hepatic, renal, blood, respiratory, or neuropsychiatric diseases; 7. Malignant tumor, lymphoma, HIV-positive, or hepatitis; 8. Uncontrolled hypertension (systolic BP \>160 mm Hg or a diastolic BP \>100 mmHg on at least two consecutive readings); 9. Patients with active bleeding, major surgery or trauma within 3 months and cerebrovascular accident within 6 months; 10. History of anemia (hemoglobin\<90g/L) or thrombocytopenia (thrombocyte\<90×109/L); 11. Multi-vessel disease with non-culprit vessel intervention; 12. Breastfeeding, pregnant, or potentially fertile women; 13. Patients who have known to be allergic to Shenfu Injection or its components or patients with serious adverse effect; 14. Patients with potential contraindication to CMR; 15. Participation in other clinical trial in recent 3 months; 16. Patients who cannot complete this trial or comply with the protocol.